Role of PARP Inhibitors in Ovarian Cancer
Received Date: Feb 01, 2025 / Published Date: Feb 28, 2025
Abstract
Ovarian cancer, a leading cause of gynecologic cancer mortality, is characterized by DNA repair deficiencies in up to 50% of cases, particularly in BRCA-mutated and homologous recombination-deficient (HRD) tumors. Poly (ADPribose) polymerase (PARP) inhibitors, such as olaparib, niraparib, and rucaparib, exploit these vulnerabilities, offering significant therapeutic advances. This article reviews the mechanisms, clinical trial outcomes, and challenges of PARP inhibitors in ovarian cancer treatment. Results demonstrate prolonged progression-free survival (PFS) in maintenance and recurrent settings, though resistance remains a hurdle. Future directions include combination therapies and biomarker development to optimize patient selection.
Citation: James PP (2025) Role of PARP Inhibitors in Ovarian Cancer. CurrentTrends Gynecol Oncol, 10: 260.
Copyright: 漏 2025 James PP. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
天美传媒 Access Journals
Article Usage
- Total views: 368
- [From(publication date): 0-0 - Dec 13, 2025]
- Breakdown by view type
- HTML page views: 283
- PDF downloads: 85
